Professor, Medicine, University of Washington School of Medicine
Oncology
Dr. Elihu H. Estey, MD
|
|
Give Review
Elihu Estey is an expert in the field of Oncology. He went to medical school at Johns Hopkins University School of Medicine. Johns Hopkins University School of Medicine is a top medical college. Johns Hopkins University School of Medicine has a rank of 3 in research and a 29 in primary care He has 2 awards "America's Top Doctors" and "America's Top Doctors for Cancer". Elihu H. Estey is a published doctor and has 101 publications published. The lastest was: 'Relationhip between event-free survival and overall survival in acute myeloid leukemia: A report from SWOG, HOVN/SAKK, and MRC/NCRI.' Elihu H. Estey is registered with Medicare and accepts Medicare payments.
Publications
- A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed Acute myeloid leukemia and high-risk myelodysplastic syndrome.
- Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?
- Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with Acute myeloid leukaemia or high-risk MDS.
- Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: ...
- Reply to D. Przepiorka et al.
- Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact on Outcome in Acute Myeloid Leukemia.
- Effect of genetic profiling on prediction of therapeutic resistance and survival in adult Acute myeloid leukemia.
- Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in Acute myeloid leukemia.
- Low platelet count reduces subsequent complete remission rate despite marrow with <5% blasts after AML induction therapy.
- Resistance prediction in AML: Analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center.
- Idarubicin, cytarabine, and pravastatin as induction therapy for untreated Acute myeloid leukemia and high-risk myelodysplastic syndrome.
- Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed Acute myeloid leukemia and Acute lymphoblastic leukemia.
- Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD Acute myeloid leukemia.
- G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of Acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloprolif...
- Allogeneic hematopoietic cell transplantation for Acute myeloid leukemia in older adults.
- Central Nervous System Involvement in Acute Myeloid Leukemia Patients Undergoing Hematopoietic Cell Transplantation.
- Correlation between peripheral blood and bone marrow regarding FLT3-ITD and NPM1 mutational status in patients with Acute myeloid leukemia.
- Acute myeloid leukemia: 2014 Update on risk-stratification and management.
- Value of Routine 'Day 14' Marrow Exam in Newly-Diagnosed AML.
- Management of older or unfit patients with Acute myeloid leukemia.
- Factors associated with early reinduction chemotherapy for adults with Acute myeloid leukemia.
- Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia.
- The past and future of CD33 as therapeutic target in Acute myeloid leukemia.
- Rapid rate of peripheral blood blast clearance accurately predicts complete remission in Acute myeloid leukemia.
- A Phase I Study of Fludarabine, Cytarabine, and Oxaliplatin Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia.
- Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson.
- Prediction of adverse events during Intensive Induction chemotherapy for Acute myeloid leukemia or high-grade myelodysplastic syndromes.
- Treosulfan, Fludarabine, and 2-Gy Total Body Irradiation Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Acute ...
- Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in Acute myeloid leukaemia.
- Cyclosporine modulation of multidrug resistance in combination with pravastatin, mitoxantrone and etoposide for adult patients with relapsed/refractory Acute myeloid l...
- Single-Agent Liposomal All-Trans-Retinoic Acid as Initial Therapy for Acute Promyelocytic Leukemia: 13-Year Follow-Up Data.
- The role of quizartinib in the treatment of Acute myeloid leukemia.
- Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and Acute myeloid leukemia.
- Outpatient management following intensive induction or salvage chemotherapy for Acute myeloid leukemia.
- Outcome of adolescents and young adults with Acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials.
- The NCI common toxicity criteria and treatment-associated mortality in Acute myeloid leukemia.
- A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed Acute myeloid leukaemia.
- Significance of minimal residual Disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission.
- Prophylactic use of granulocyte colony-stimulating factor after consolidation therapy with high-dose cytarabine for Acute myeloid leukemia.
- Acute myeloid leukemia: 2013 update on risk-stratification and management.
- Decitabine in Older Adults With Acute Myeloid Leukemia: Why Was the Dream Broken?
- Influence of obesity on efficacy and toxicity of induction chemotherapy in patients with newly diagnosed Acute myeloid leukemia.
- The proportion of CD34(+)CD38(low or neg) myeloblasts, but not side population frequency, predicts initial response to induction therapy in patients with newly diagnos...
- Significance of FAB subclassification of "Acute Myeloid Leukemia, NOS" in the 2008 WHO classification: analysis of 5,848 newly diagnosed patients.
- Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage th...
- Who benefits from maintenance therapy in Acute promyelocytic leukemia?
- Management of Acute promyelocytic leukemia: implications for treatment of other cancers.
- Be quick, but don't hurry.
- Treatment of AML: resurrection for gemtuzumab ozogamicin?
- Pre-Transplant Therapy with Azacitidine Versus Induction Chemotherapy and Post-Transplant Outcome in Patients with MDS.
- Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.
- Phase 2 trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated Acute myeloid leukemia.
- Prediction of early death after induction therapy for newly diagnosed Acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment.
- Impact of residual normal metaphases in core binding factor Acute myeloid leukemia.
- Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory Acute myeloid leukaemia.
- Newly Diagnosed Acute Promyelocytic Leukemia: Arsenic Moves Front and Center.
- Impact of pretransplantation minimal residual Disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation fo...
- Outpatient management following intensive induction chemotherapy for myelodysplastic syndromes and Acute myeloid leukemia: a pilot study.
- Shortcomings in the clinical evaluation of new drugs: Acute myeloid leukemia as paradigm.
- Effect of complete remission and responses less than complete remission on survival in Acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest...
- A distinct subset of self-renewing human memory CD8+ T Cells survives cytotoxic chemotherapy.
- Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or pri...
- Targeting the Leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.
- Incorporating novel treatment strategies into conventional therapy.
- Management of Acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
- Constitutional hypomorphic telomerase mutations in patients with Acute myeloid leukemia.
- Time from diagnosis to treatment initiation predicts survival in younger, but not older, Acute myeloid leukemia patients.
- Patient-specific dose finding based on bivariate outcomes and covariates.
- Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for Acute myeloid leukemia.
- Treatment of core-binding-factor in Acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free s...
- The prognostic significance of serum beta2 microglobulin levels in Acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients.
- Phase I study of alternate-week administration of tipifarnib in patients with Myelodysplastic syndrome.
- Epidemiology of Myelodysplastic syndromes.
- Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in Acute myeloid leukemia and myelodysplastic syndrome.
- Comparative analysis of genes regulated in Acute myelomonocytic leukemia with and without inv(16)(p13q22) using microarray techniques, real-time PCR, immunohistochemis...
- Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent Acute promyelocytic leukemia.
- Advances in the management of AML in the elderly.
- Simultaneous activation of multiple signal transduction pathways confers poor prognosis in Acute myelogenous leukemia.
- High-dose cytosine arabinoside in the treatment of Acute myeloid leukemia: Review of three randomized trials.
- General approach to, and perspectives on clinical research in, older patients with newly diagnosed Acute myeloid leukemia.
- Some ethical issues in phase II trials in Acute leukemia.
- Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies.
- Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations.
- Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive Acute myeloid leukemia in first recurrence.
- "3+7" therapy for the treatment of Acute myeloid leukemia. CON.
- Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in Acute myeloid leukemia and myelodysplastic syndromes.
- Phase II study of R115777, a farnesyl transferase inhibitor, in Myelodysplastic syndrome.
- PML-RARalpha is associated with leptin-receptor induction: the role of mesenchymal stem Cell-derived adipocytes in APL Cell survival.
- Expression of CD2 in Acute promyelocytic leukemia correlates with short form of PML-RARalpha transcripts and poorer prognosis.
- Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML.
- The clinical significance of soluble CD86 levels in patients with Acute myeloid leukemia and myelodysplastic syndrome.
- Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for Myeloid malignancies in patients older than 55 years.
- Adaptive randomization in a treatment study of patients with adverse karyotype Acute myeloid leukemia.
- Early blast clearance by remission induction as a prognostic factor in Acute myeloid leukemia.
- Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in Myelodysplastic syndrome.
- Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions.
- Contribution of beta-2 microglobulin levels to the prognostic stratification of survival in patients with Myelodysplastic syndrome (MDS).
- New designs for phase 2 clinical trials.
- Variability in management of hematologic malignancy patients with venous thromboembolism and chemotherapy-induced thrombocytopenia.
- Relationhip between event-free survival and overall survival in Acute myeloid leukemia: A report from SWOG, HOVN/SAKK, and MRC/NCRI.
Schools
Johns Hopkins University School Of Medicine
Bellevue Hospital Center
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Breast Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
Education
-
University of Texas Health Science Center -
NYU School of Medicine -
Johns Hopkins University School of Medicine
Hospital
-
University of Washington Medical Center
Drug Facts
| NPI NUMBER | 1043319023 | |
| NPPES Provider LastName | ESTEY | |
| NPPES Provider FirstName | ELIHU | |
| NPPES Provider ZIPCode | 981091023 | |
| NPPES Provider State | WA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 126.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1043319023 |
| Last Name Of The Provider | ESTEY |
| First Name Of The Provider | ELIHU |
| View All |
Similar Doctors
|
|
Dr. Albert B. Einstein, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. George E. Georges, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Day F. Hills, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hugh L. Straley, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul V. O'Donnell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robin L. Jones, MD |
|
Dr. Anne C. Silva, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Derek L. Stirewalt, MD
This Doctor is OpenDoctor Recommended.
|